Market Announcement

11 November 2026

Clarity Pharmaceuticals Ltd (ASX: CU6) – Trading Halt

Trading in the securities of Clarity Pharmaceuticals Ltd ('CU6') will be halted at the request of CU6, pending the release of an announcement by CU6.

Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of:

- the commencement of normal trading on Friday, 13 November 2026; or
- the release of the announcement to the market.

CU6's request for a trading halt is attached below for the information of the market.

Issued by

ASX Supervision

11 November 2026

ASX Market Announcements Office
ASX Limited
39 Martin Place, Sydney NSW 2000

By email: tradinghaltssydney@asx.com.au

Request for Trading Halt – Clarity Pharmaceuticals Limited (ASX: CU6)

Pursuant to ASX Listing Rule 17.1, Clarity Pharmaceutical Limited (ACN: 143 005 341) ("Clarity") requests that a trading halt be granted by the Australian Securities Exchange in respect of its securities with effect from commencement of trading on the 11th of November 2026.

For the purposes of Listing Rule 17.1, Clarity advises that:

1. **Reason for halt**: the trading halt is requested pending a material announcement by Clarity in relation to a United States Food and Drug Administration response regarding Copper-64 SAR bisPSMA;
2. **Duration for trading halt**: Clarity requests that the trading halt continue until the earlier of such time as it makes an announcement to the market or the commencement of normal trading on 12 November 2026;
3. **No reason**: Clarity is not aware of any reason why the trading halt should not be granted; and
4. **Further information**: Clarity is not aware of any further information which needs to be disclosed to the market at the time of seeking the trading halt.

Yours sincerely,



Robert Vickery

Company Secretary